The human leukemic oncogene MLL-AF4 promotes hyperplastic growth of hematopoietic tissues in Drosophila larvae

[1]  E. Clappier,et al.  The KMT2A recombinome of acute leukemias in 2023 , 2023, Leukemia.

[2]  S. Armstrong,et al.  The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia , 2023, Nature.

[3]  V. Honti,et al.  Peeling Back the Layers of Lymph Gland Structure and Regulation , 2022, International journal of molecular sciences.

[4]  Elias A. Rahal,et al.  Expression of chronic myeloid leukemia oncogenes BCR-ABL P210 and BCR-ABL T315I affect cellular and humoral innate immunity in Drosophila melanogaster , 2022, microPublication biology.

[5]  A. Mead,et al.  A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program , 2021, Nature Communications.

[6]  M. Konopleva,et al.  Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience , 2021, Blood advances.

[7]  R. Marschalek,et al.  The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(4;11) , 2021, Oncogene.

[8]  M. Konopleva,et al.  Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements , 2021, Blood Cancer Journal.

[9]  N. Perrimon,et al.  Preparation of Drosophila Larval Blood Cells for Single-cell RNA Sequencing. , 2021, Bio-protocol.

[10]  R. Marschalek,et al.  The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(6;11) , 2021, Oncogene.

[11]  G. Sauvageau,et al.  A genetic screen in Drosophila uncovers the multifaceted properties of the NUP98-HOXA9 oncogene , 2021, PLoS genetics.

[12]  Y. Yao,et al.  Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth , 2021, Theranostics.

[13]  Editor's evaluation: Paths and pathways that generate cell-type heterogeneity and developmental progression in hematopoiesis , 2021 .

[14]  W. Foulkes,et al.  Achieving clinical success with BET inhibitors as anti-cancer agents , 2021, British Journal of Cancer.

[15]  V. Honti,et al.  There and back again: The mechanisms of differentiation and transdifferentiation in Drosophila blood cells. , 2020, Developmental biology.

[16]  R. Nasr,et al.  The Leukemic Fly: Promises and Challenges , 2020, Cells.

[17]  L. Jin,et al.  The Posterior Signaling Center Is an Important Microenvironment for Homeostasis of the Drosophila Lymph Gland , 2020, Frontiers in Cell and Developmental Biology.

[18]  R. Marschalek.  The reciprocal world of MLL fusions: A personal view. , 2020, Biochimica et biophysica acta. Gene regulatory mechanisms.

[19]  R. Slany.  MLL fusion proteins and transcriptional control. , 2020, Biochimica et biophysica acta. Gene regulatory mechanisms.

[20]  N. Perrimon,et al.  Single-cell transcriptome maps of myeloid blood cell lineages in Drosophila , 2020, Nature Communications.

[21]  K. Ross,et al.  A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. , 2019, Cancer cell.

[22]  R. Nasr,et al.  Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening , 2019, Haematologica.

[23]  U. Banerjee,et al.  Drosophila as a Genetic Model for Hematopoiesis , 2019, Genetics.

[24]  S. Armstrong,et al.  The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. , 2018, Blood.

[25]  H. Bourbon,et al.  Genome Regulation by Polycomb and Trithorax: 70 Years and Counting , 2017, Cell.

[26]  T. Cheng,et al.  PBX3 is essential for leukemia stem cell maintenance in MLL‐rearranged leukemia , 2017, International journal of cancer.

[27]  H. Munshi,et al.  BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects , 2016, OncoTargets and therapy.

[28]  R. Majeti,et al.  ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia. , 2016, Cancer discovery.

[29]  R. Slany.  The molecular mechanics of mixed lineage leukemia , 2016, Oncogene.

[30]  S. Malek,et al.  Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner , 2016, Leukemia.

[31]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[32]  Bo Wen,et al.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. , 2015, Cancer cell.

[33]  S. Armstrong,et al.  AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. , 2014, Cancer cell.

[34]  E. Olhava,et al.  DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[35]  S. Bras,et al.  Pontin is a critical regulator for AML1-ETO-induced leukemia , 2014, Leukemia.

[36]  Phillip J. Wyss,et al.  Discovery of MLL1 binding units, their localization to CpG Islands, and their potential function in mitotic chromatin , 2013, BMC Genomics.

[37]  N. Perrimon,et al.  FlyPrimerBank: An Online Database for Drosophila melanogaster Gene Expression Analysis and Knockdown Evaluation of RNAi Reagents , 2013, G3: Genes, Genomes, Genetics.

[38]  E. Olhava,et al.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.

[39]  S. Armstrong,et al.  Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. , 2013, Blood.

[40]  J. Rowley,et al.  PBX3 is an important cofactor of HOXA9 in leukemogenesis. , 2013, Blood.

[41]  S. Bray,et al.  Notch cooperates with Lozenge/Runx to lock haemocytes into a differentiation programme , 2013, Development.

[42]  H. Richardson,et al.  An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery , 2012, Disease Models & Mechanisms.

[43]  A. Shilatifard,et al.  The super elongation complex (SEC) family in transcriptional control , 2012, Nature Reviews Molecular Cell Biology.

[44]  Jolanta Grembecka,et al.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.

[45]  C. Allis,et al.  Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes , 2011, Proceedings of the National Academy of Sciences.

[46]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[47]  S. Armstrong,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[48]  Yi Zhang,et al.  DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. , 2011, Blood.

[49]  U. Banerjee,et al.  Genetic manipulation of AML1-ETO-induced expansion of hematopoietic precursors in a Drosophila model. , 2010, Blood.

[50]  M. Diaz,et al.  The PHD3 Domain of MLL Acts as a CYP33-Regulated Switch between MLL-Mediated Activation and Repression, , 2010, Biochemistry.

[51]  V. Honti,et al.  Cell lineage tracing reveals the plasticity of the hemocyte lineages and of the hematopoietic compartments in Drosophila melanogaster. , 2010, Molecular immunology.

[52]  T. Dingermann,et al.  The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. , 2010, Blood.

[53]  A. Shilatifard,et al.  Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). , 2010, Genes & development.

[54]  A. Shilatifard,et al.  AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. , 2010, Molecular cell.

[55]  O. Heidenreich,et al.  A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO , 2009, Proceedings of the National Academy of Sciences.

[56]  Akihiko Yokoyama,et al.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes. , 2008, Cancer cell.

[57]  A. Chinnaiyan,et al.  A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. , 2007, Blood.

[58]  M. Cleary,et al.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.

[59]  I. Andó,et al.  Definition of Drosophila Hemocyte Subsets by Cell-Type Specific Antigens , 2007, Acta biologica Hungarica.

[60]  V. Hartenstein,et al.  A Hedgehog- and Antennapedia-dependent niche maintains Drosophila haematopoietic precursors , 2007, Nature.

[61]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[62]  Thomas A. Milne,et al.  Physical Association and Coordinate Function of the H3 K4 Methyltransferase MLL1 and the H4 K16 Acetyltransferase MOF , 2005, Cell.

[63]  C. J. Evans,et al.  The Drosophila lymph gland as a developmental model of hematopoiesis , 2005, Development.

[64]  Brian Stramer,et al.  Live imaging of wound inflammation in Drosophila embryos reveals key roles for small GTPases during in vivo cell migration , 2005, The Journal of cell biology.

[65]  V. Honti,et al.  Characterization of the grappa Gene, the Drosophila Histone H3 Lysine 79 Methyltransferase , 2005, Genetics.

[66]  R. Paro,et al.  Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and chromosome morphology , 2004, Oncogene.

[67]  W. Herr,et al.  Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression , 2004, Molecular and Cellular Biology.

[68]  Arndt Borkhardt,et al.  Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization , 2004, Molecular and Cellular Biology.

[69]  A. Goto,et al.  Drosophila hemolectin gene is expressed in embryonic and larval hemocytes and its knock down causes bleeding defects. , 2003, Developmental biology.

[70]  R. Klapper,et al.  The two origins of hemocytes in Drosophila , 2003, Development.

[71]  N. Zeleznik-Le,et al.  MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  C. Ferraz,et al.  The Leucine Zipper Motif of the Drosophila AF10 Homologue Can Inhibit PRE-Mediated Repression: Implications for Leukemogenic Activity of Human MLL-AF10 Fusions , 2003, Molecular and Cellular Biology.

[73]  Thomas A Milne,et al.  MLL targets SET domain methyltransferase activity to Hox gene promoters. , 2002, Molecular cell.

[74]  M. Birke,et al.  The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. , 2002, Nucleic acids research.

[75]  M. Diaz,et al.  Protein Interactions of the MLL PHD Fingers Modulate MLL Target Gene Regulation in Human Cells , 2001, Molecular and Cellular Biology.

[76]  R. Lanot,et al.  Postembryonic hematopoiesis in Drosophila. , 2001, Developmental biology.

[77]  C. Croce,et al.  Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality , 2001, Oncogene.

[78]  M. Cleary,et al.  HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis , 2000, Oncogene.

[79]  T Marty,et al.  Regulation of Hox target genes by a DNA bound Homothorax/Hox/Extradenticle complex. , 1999, Development.

[80]  J. Juang,et al.  Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis , 1999, Oncogene.

[81]  J. Frestedt,et al.  AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments. , 1998, Blood.

[82]  S. Korsmeyer,et al.  Altered Hox expression and segmental identity in Mll-mutant mice , 1995, Nature.

[83]  D. Keene,et al.  Peroxidasin: a novel enzyme‐matrix protein of Drosophila development. , 1994, The EMBO journal.

[84]  H. Alder,et al.  The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene , 1992, Cell.

[85]  Michael L. Cleary,et al.  Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias , 1992, Cell.

[86]  G. Evans,et al.  A trithorax–like gene is interrupted by chromosome 11q23 translocations in acute leukaemias , 1992, Nature Genetics.

[87]  R. Rizki,et al.  Lamellocyte differentiation in Drosophila larvae parasitized by Leptopilina. , 1992, Developmental and comparative immunology.

[88]  J. Rowley,et al.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[89]  L. Waltzer,et al.  From Drosophila Blood Cells to Human Leukemia. , 2018, Advances in experimental medicine and biology.

[90]  G. Sauvageau,et al.  Human NUP98-HOXA9 promotes hyperplastic growth of hematopoietic tissues in Drosophila. , 2017, Developmental biology.

[91]  V. Honti,et al.  The cell-mediated immunity of Drosophila melanogaster: hemocyte lineages, immune compartments, microanatomy and regulation. , 2014, Developmental and comparative immunology.

[92]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[93]  I. Andó,et al.  Supplemental Experimental Procedures Drosophila Strains , 2022 .